

1006 Rec'd PCT/PTO 14 SEP 2005

PCT
PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No: 10/539,172
Applicant(s): Bover Fuentes, et al.
Filed: June 14, 2005
Title: Combinations of Growth and Hormone Regulating Factors for the Treatment of Neoplasia
TC/A.U.: Unassigned
Examiner: Unassigned
Docket: 976-25 PCT/US

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

on 9/12/05, Signature Julie R. Watts

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in the 37 C.F.R. §1.56, Applicant submits herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

UNITED STATES PATENTS

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Gandolf, et al.	5,894,018	April 13, 1999

FOREIGN PATENT DOCUMENTS

<u>COUNTRY</u>	<u>PUBLICATION NO.</u>	<u>PUBLICATION DATE</u>
Great Britain	GB 2 228 262 A	August 22, 1990
PCT	WO 94/10202 A	May 11, 1994
PCT	WO 98/27111 A	June 25, 1998

NON-PATENT PUBLICATIONS

1. Camby, I., et al., "Characterization of the Influence of Anti-Hormone and/or Anti-Growth Factor Neutralizing Antibodies on Cell Clone Architecture and the Growth of Human Neoplastic Astrocytic Cell Lines", *Journal of Neuro-Oncology* 1994, 20(1):67-80.

Each of the above references were listed in the International Search Report issued in the corresponding International Application. A copy of the International Search Report accompanies this IDS.


Copies of the cited references should have been provided by the International Searching Authority. Upon receipt of a Notification of Acceptance of Application indicating what items have been received by the Patent and Trademark Office, Applicant will review the same to ensure that the references were provided.

A separate listing of all the references has been set forth on the enclosed form PTO-1449. The Examiner is respectfully requested to consider these references in their entirety, and to indicate that he or she has done so by initialing the enclosed Patent and Trademark Office Form 1449.

If the Examiner has any questions relating to the present communication he or she is invited to contact Applicant's agent at the telephone number set forth below.

Applicant does not believe that any fees are due. However, if any fees are due, please charge Deposit Account No. 08-2461.

Respectfully submitted,



Edna I. Gergel, Ph.D.
Registration No.: 50,819
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
EIG:jlw
209885_1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
976-25 PCT/USSERIAL NO.
10/539,172APPLICANT
Bover Fuentes, et al.CONFIRMATION NO.
UnassignedFILING DATE
June 14, 2005GROUP
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
		5,894,018	4/13/99	Gandolf, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		GB 2228262 A	8/22/90	Great Britain				
		WO 94/10202A	5/11/94	PCT				
		WO 98/27111A	6/25/98	PCT				
		WO 02/45738A	6/13/02	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1.	Camby, I., et al., "Characterization of the Influence of Anti-Hormone and/or Anti-Growth Factor Neutralizing Antibodies on Cell Clone Architecture and the Growth of Human Neoplastic Astrocytic Cell Lines", <i>Journal of Neuro-Oncology</i> 1994, 20(1):67-80.
--	--	----	---

209886_1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.